ResMed (RMD) Reports In-Line Q1 EPS

ResMed (NYSE: RMD) reported Q1 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $380.4 million versus the consensus estimate of $375 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)
• OLB Group narrows net loss 50% as revenue falls in Q2 2026